CANLAC LACTULOSE PLANT FOR CANADA

16 March 1992

Canlac Corp of Canada has ann-ounced that it is to build a new pharmaceutical production facility in Victoriaville, Quebec, as a joint venture with Ault Foods, a subsidiary of John Labatt Ltd, ACIC (Canada) Inc and the Willis Management Group. The C$12 million facility will be a single-product plant making lactulose, a natural source laxative which is sold over-the-counter in Europe and which has recently been approved for OTC sale in Canada.

The plant is expected to be in commercial production by the beginning of 1993 with world-scale production. Its capacity is targeted for Canada and the export market, focusing initially on Europe and later, following regulatory approval, the USA. This will be the first plant in the world which fully integrates the lactulose production process starting with whey perm-eate, according to a Canlac press release, and the only North American plant manufacturing lactulose.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight